CAJ | 학술논문

目的：观察自体DC/CIK细胞联合肝动脉化疗栓塞术（TACE）在中晚期肝癌治疗中的临床疗效。方法：60例中晚期肝癌患者随机分为联合治疗组和单纯TACE组，联合治疗组采用自体DC/CIK细胞联合TACE治疗（n＝32），单纯TACE组采用单纯TACE治疗（n＝28），观察两组治疗前后肿瘤大小、甲胎蛋白（AFP）、生存率、中位生存期、生活质量有无差异。结果：（1）经过治疗，联合治疗组有效率87．50％，单纯TACE组有效率64．29％，差异有统计学意义（P＜0．05）；（2）经过治疗两组血清AFP均下降，但差异无统计学意义（P＞0．05）；（3）联合治疗组治疗0．5年生存率96．88％，1年生存率84．38％，2年生存率65．63％，中位生存期21个月；单纯TACE组治疗后0．5年生存率92．85％，1年生存率64．29％，2年生存率42．86％，中位生存期17个月，差异无统计学意义（P＞0．05）；（4）治疗后联合治疗组生活质量明显提高，差异有统计学意义（P＜0．05）。结论：DC/CIK联合TACE治疗能够控制肿瘤大小、降低AFP，延长中晚期肝癌患者的生存时间，提高患者的生存率，特别是改善患者生活质量，是中晚期肝癌行之有效的治疗方法，值得临床进一步推广。
목적：관찰자체DC/CIK세포연합간동맥화료전새술（TACE）재중만기간암치료중적림상료효。방법：60례중만기간암환자수궤분위연합치료조화단순TACE조，연합치료조채용자체DC/CIK세포연합TACE치료（n＝32），단순TACE조채용단순TACE치료（n＝28），관찰량조치료전후종류대소、갑태단백（AFP）、생존솔、중위생존기、생활질량유무차이。결과：（1）경과치료，연합치료조유효솔87．50％，단순TACE조유효솔64．29％，차이유통계학의의（P＜0．05）；（2）경과치료량조혈청AFP균하강，단차이무통계학의의（P＞0．05）；（3）연합치료조치료0．5년생존솔96．88％，1년생존솔84．38％，2년생존솔65．63％，중위생존기21개월；단순TACE조치료후0．5년생존솔92．85％，1년생존솔64．29％，2년생존솔42．86％，중위생존기17개월，차이무통계학의의（P＞0．05）；（4）치료후연합치료조생활질량명현제고，차이유통계학의의（P＜0．05）。결론：DC/CIK연합TACE치료능구공제종류대소、강저AFP，연장중만기간암환자적생존시간，제고환자적생존솔，특별시개선환자생활질량，시중만기간암행지유효적치료방법，치득림상진일보추엄。
Objective To investigate the clinical efficacy of autologous dendritic cells and cytokine-induced killer cells (DC/CIK) combined with transcatheter arterial chemoembolization (TACE) in the treatment of moderate and advanced hepatocellular carcinoma (HCC). Methods Sixty patients with moderste and advanced HCC were randomly divided into two groups: the experimental group (n = 32), in which the treatment of DC/CIK combined with TACE was used, and the control group (n=28), in which TACE treatment was used only. The parameters of tumor size , serum alpha-fetoprotein , survival rate , the median survival time and quality of life , were detected in patients of the two groups before and after corresponding therapy . Results ( 1 ) After receiving corresponding treatments, the efficient rates of DC/CIK combined with TACE and TACE only were 87.50% and 64.29%, respectively, with significant difference;(2) The level of serum AFP decreased in the two groups after corresponding treatment, with no significant difference; (3) The 6-month survival rate was 96.88%and 92.85%, and the 1-year survival rate was 84.38%and 64.29%, the 2-year survival rate was 65.63%and 42.86%in the experimental group and in the control group, respectively. And the median survival time was 21 months and 17 months in the experimental group and the control group, respectively, with no significant difference; (4) The quality of life was improved significantly in the DC/CIK combined with TACE group after treatment. Conclusions Administration of DC and CIK combined with TACE can prolong the survival time, increase the survival rate and especially improve the life quality of HCC patients. It is a promising approach for the treatment of patients with moderate and advanced HCC.